Canadian cannabis giant Aurora Cannabis and Germany’s Demecan have both announced the launch of their first domestically grown cannabis products into the German medical market.
The passage of CanG in April 2024 saw the severely restrictive cap on those licensed to grow cannabis in the country, alongside the tender process to receive a domestic cultivation license.
In July, Business of Cannabis reported that Tilray, Aurora and Demecan, had all been granted the first licenses in half a decade to cultivate cannabis in Germany.
These three operators were all winners of the original tender to produce medical cannabis under strict production quotas for the German government.
Now, Aurora and Demecan’s first German-grown products are becoming available for German patients.
Read more at Business of Cannabis
